For the treatment of chronic autoimmune diseases such as inflammatory bowel disease, diabetes and MS
BioRap Technologies, the technology transfer company of the Rappaport Institute for Biomedical Research at the Technion (Israel Institute of Technology), has entered into an agreement with Pfizer which aims to further develop a monoclonal antibody into potential new treatment options for chronic autoimmune diseases such as inflammatory bowel disease, diabetes and multiple sclerosis.
The tie-up is based on a breakthrough made by Prof. Nathan Karin and his research team at the Rappaport Institute. The team developed a novel monoclonal antibody that, when bound with a certain immune checkpoint molecule, drives the activity of regulatory T-cells, a cell type that plays an important role in controlling autoimmunity.
Under the terms of the agreement, Pfizer has an exclusive option to obtain a licence to the monoclonal antibody programme. If the option is exercised, Pfizer will further develop and potentially commercialise any resulting product.
BioRap Technologies is eligible to receive potential milestone-based financial support from Pfizer linked to reaching agreed milestones. BioRap will receive an undisclosed upfront payment and royalties on sales from any product that may be successfully commercialised as a result of the collaboration.
Michael Vincent, Chief Scientific Officer, Inflammation & Immunology, Pfizer, said: 'We believe that the work of Professor Karin and his team has shown significant potential to create therapeutic value for patients with chronic autoimmune diseases, and we look forward to this collaboration and to what it may yield.'